InvestorsHub Logo
Followers 2
Posts 3055
Boards Moderated 0
Alias Born 07/16/2007

Re: None

Wednesday, 10/07/2009 3:40:55 PM

Wednesday, October 07, 2009 3:40:55 PM

Post# of 346054
Finally, an employee who has worked for someone other than a micro cap company.

Dr. Amy Brideau-Andersen will be directing the new Anti-Viral Research Group. Before joining Peregrine in 2006, she played an important role in the discovery and development of novel anti-viral drugs at Valeant Pharmaceuticals and at Maxygen, Inc.

Maxygen, Inc.(NasdaqGM: MAXY)
Real-Time: 6.85 +0.07 (1.03%) 3:27pm
Full Time Employees: 72
Revenue (ttm): 113.41M

VALEANT PHARMA INTL(NYSE: VRX)
Real-Time: 29.09 +0.30 (1.04%) 3:29pm EThelp
Full Time Employees: 2,331
Revenue (ttm): 721.06M


Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
Brideau-Andersen AD, Huang X, Sun SC, Chen TT, Stark D, Sas IJ, Zadik L, Dawes GN, Guptill DR, McCord R, Govindarajan S, Roy A, Yang S, Gao J, Chen YH, Skartved NJ, Pedersen AK, Lin D, Locher CP, Rebbapragada I, Jensen AD, Bass SH, Nissen TL, Viswanathan S, Foster GR, Symons JA, Patten PA.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8269-74. Epub 2007 May 9.


2: Interference of hepatitis C virus RNA replication by short interfering RNAs.
Kapadia SB, Brideau-Andersen A, Chisari FV.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2014-8. Epub 2003 Feb 3.

PMID: 12566571 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC | at journal site
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News